Literature DB >> 8287031

Dose-dependent hepatic handling of l-propranolol determined by multiple indicator dilution method: influence of tissue binding of l-propranolol on its hepatic elimination.

S Miyauchi1, Y Sawada, T Iga, M Hanano, Y Sugiyama.   

Abstract

Concentration-dependency in the hepatic elimination of l-propranolol (l-PR) was investigated over a wide range of concentrations from 60 to 2200 microM in an isolated rat liver perfusion system. Under the steady-state condition produced by unlabeled l-PR at various concentrations, 3H-l-PR and 14C-inulin were bolusly injected into the portal vein, and the outflow was collected at 0.5 s intervals over 30 s. Up to 300 microM, the instantaneous hepatic availability of l-PR was approximately 4%, while it abruptly increased when the perfusate concentration exceeded 300 microM. To determine which process (influx or efflux or sequestration process) caused the nonlinearity, we calculated the rate constants k1 (influx), k2 (efflux), and k3 (sequestration) based on the "distributed" model. With increasing l-PR concentration in the perfusate, k2 increased approximately two times, whereas k3 decreased to approximately one-half. In contrast, k1 was independent of the perfusate concentration. The concentration-dependency of k2 was explained by saturation of l-PR tissue binding, since the tissue unbound fraction of l-PR obtained with liver homogenates and isolated hepatocytes increased approximately two times. The efflux and sequestration clearances were then normalized by the unbound fractions in the liver. The efflux clearance for unbound l-PR was constant irrespective of the perfusate concentration, whereas the sequestration clearance for unbound l-PR (CL(int) showed Michaelis-Menten type saturation (Km = 28 microM, Vmax = 2.8 mumol/min/g liver, alpha (nonspecific) = 2- ml/min/g liver).(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8287031     DOI: 10.1248/bpb.16.1019

Source DB:  PubMed          Journal:  Biol Pharm Bull        ISSN: 0918-6158            Impact factor:   2.233


  7 in total

Review 1.  Prediction of hepatic clearance in human from in vitro data for successful drug development.

Authors:  Masato Chiba; Yasuyuki Ishii; Yuichi Sugiyama
Journal:  AAPS J       Date:  2009-04-30       Impact factor: 4.009

2.  Analysis of nonlinear hepatic clearance of a cyclopentapeptide, BQ-123, with the multiple indicator dilution method using the dispersion model.

Authors:  A Hisaka; T Nakamura; Y Sugiyama
Journal:  Pharm Res       Date:  1999-01       Impact factor: 4.200

3.  Determination of the rate-limiting step in the hepatic elimination of YM796 by isolated rat hepatocytes.

Authors:  T Iwatsubo; H Suzuki; Y Sugiyama
Journal:  Pharm Res       Date:  1999-01       Impact factor: 4.200

4.  Uptake is the rate-limiting step in the overall hepatic elimination of pravastatin at steady-state in rats.

Authors:  M Yamazaki; S Akiyama; R Nishigaki; Y Sugiyama
Journal:  Pharm Res       Date:  1996-10       Impact factor: 4.200

5.  Membrane transport in hepatic clearance of drugs. I: Extended hepatic clearance models incorporating concentration-dependent transport and elimination processes.

Authors:  Y Kwon; M E Morris
Journal:  Pharm Res       Date:  1997-06       Impact factor: 4.200

6.  H3 Propranolol serum levels following lidocaine administration in rats with CCL4 induced liver damage.

Authors:  A Kotsiou; M Tsamouri; S Anagnostopoulou; M Tzivras; E Vairactaris; C Tesseromatis
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2006 Apr-Jun       Impact factor: 2.441

Review 7.  Recent advances in carrier-mediated hepatic uptake and biliary excretion of xenobiotics.

Authors:  M Yamazaki; H Suzuki; Y Sugiyama
Journal:  Pharm Res       Date:  1996-04       Impact factor: 4.200

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.